Drugs / Pasritamig
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07860255 | Nov 2026 → Nov 2028 expected | prostate cancer | Fred Hutchinson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07319871 | Jan 2026 → Jan 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07082920 | Jul 2025 → Nov 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06095089 | Nov 2023 → Jun 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04898634 | Jul 2021 → Mar 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04644770 | Nov 2020 → Dec 2026 expected | adenocarcinoma, prostate neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07225946 | Dec 2025 → Nov 2027 expected | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07164443 | Sep 2025 → Aug 2028 expected | metastatic prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Janssen Research & Development, LLC | Results Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer jnj.com ↗
The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. |
| 2026-02-26 | Janssen Research & Development, LLC | Results Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer jnj.com ↗ |
| 2025-06-01 | Janssen Research & Development, LLC | Results Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer jnj.com ↗ |
| 2025-06-01 | Janssen Research & Development, LLC | Results Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer jnj.com ↗
These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Janssen Research & Development, LLC | Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer jnj.com ↗ |
| 2026-02-26 | Janssen Research & Development, LLC | Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer jnj.com ↗ |
| 2025-06-01 | Janssen Research & Development, LLC | Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer jnj.com ↗ |
| 2025-06-01 | Janssen Research & Development, LLC | Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer jnj.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pasritamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07860255 ↗ |
| Known as | JNJ-78278343 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06095089 ↗ |
| Modality | Other / unclassified | “T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)” NCT04898634 ↗ |
| Route | Intravenous | “JNJ-78278343 will be administered intravenously.” NCT07082920 ↗ |
| Target | KLK2 | “Targeting Human Kallikrein 2 (KLK2)” NCT04898634 ↗ |